Table 3.
Risk based chi-square test of clinical characteristics.
| Covariates | Risk | Total | High | Low | Chi | P-value |
|---|---|---|---|---|---|---|
| Age | ≤65 | 118 (43.87%) | 62 (46.97%) | 56 (40.88%) | 0.7814 | 0.376698 |
| Age | >65 | 151 (56.13%) | 70 (53.03%) | 81 (59.12%) | ||
| Gender | Female | 103 (38.29%) | 49 (37.12%) | 54 (39.42%) | 0.0685 | 0.793606 |
| Gender | Male | 166 (61.71%) | 83 (62.88%) | 83 (60.58%) | ||
| Grade | G1–2 | 98 (36.43%) | 49 (37.12%) | 49 (35.77%) | 0.0108 | 0.917084 |
| Grade | G3 | 171 (63.57%) | 83 (62.88%) | 88 (64.23%) | ||
| Stage | Stages I–II | 124 (46.1%) | 58 (43.94%) | 66 (48.18%) | 0.3299 | 0.565703 |
| Stage | Stages III–IV | 145 (53.9%) | 74 (56.06%) | 71 (51.82%) | ||
| T | T1–2 | 68 (25.28%) | 31 (23.48%) | 37 (27.01%) | 0.2748 | 0.600126 |
| T | T3–4 | 201 (74.72%) | 101 (76.52%) | 100 (72.99%) | ||
| M | M0 | 253 (94.05) | 122 (92.42) | 131 (95.62) | 0.7228 | 0.395234 |
| M | M1 | 16 (5.95%) | 10 (7.58%) | 6 (4.38%) | ||
| N | N0–1 | 153 (56.88) | 75 (56.82%) | 78 (56.93%) | 0 | 1 |
| N | N2–3 | 116 (43.12) | 57 (43.18%) | 59 (43.07%) | ||
| FPI | ≤0 | 108 (40.15) | 73 (55.3%) | 35 (25.55%) | 23.5476 | 1.00E-06 |
| FPI | >0 | 161 (59.85) | 59 (44.7%) | 102 (74.45%) | ||
| TIDE | <0 | 84 (31.23%) | 32 (24.24%) | 52 (37.96%) | 5.266 | 0.021746 |
| TIDE | >0 | 185 (68.77%) | 100 (75.76 | 85 (62.04%) | ||
| TMB | High TMB | 135 (50.19%) | 51 (38.64%) | 84 (61.31%) | 12.937 | 0.000322 |
| TMB | Low TMB | 134 (49.81%) | 81 (61.36%) | 53 (38.69%) | ||
| ESTIMATE score | High | 134 (49.81%) | 75 (56.82%) | 59 (43.07%) | 4.5507 | 0.032905 |
| ESTIMATE score | Low | 135 (50.19%) | 57 (43.18%) | 78 (56.93%) | ||
| Immune score | High | 134 (49.81%) | 66 (50%) | 68 (49.64%) | 0 | 1 |
| Immune score | Low | 135 (50.19%) | 66 (50%) | 69 (50.36%) |
TMB, tumor mutation burden; FPI, ferroptosis potential index; TIDE, tumor immune dysfunction and exclusion.